Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1

Meili Zhang, Zhengsheng Yao, Hiral Patel, Kayhan Garmestani, Zhuo Zhang, Vladimir S. Talanov, Paul S. Plascjak, Carolyn K. Goldman, John Edward Janik, Martin W. Brechbiel, Thomas A. Waldmann

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

CD30 is a member of the TNF receptor superfamily. Overexpression of CD30 on some neoplasms versus limited expression on normal tissues makes this receptor a promising target for antibody-based therapy. Radioimmunotherapy of cancer with radiolabeled antibodies has shown promise. In this study, we evaluated the therapeutic efficacy of an anti-CD30 antibody, HeFi-1, armed with 211At in a leukemia (karpas299) model and with 90Y in a lymphoma (SUDHL-1) model. Furthermore, we investigated the combination therapy of 211At-HeFi-1 with unmodified HeFi-1 in the leukemia model. Treatment with unmodified HeFi-1 significantly prolonged the survival of the karpas299-bearing mice compared with the controls (P < 0.001). Treatment with 211At-HeFi-1 showed greater therapeutic efficacy than that with unmodified HeFi-1 as shown by survival of the mice (P < 0.001). Combining these two agents further improved the survival of the mice compared with the groups treated with either 211At-HeFi-1 (P < 0.05) or unmodified HeFi-1 (P < 0.001) alone. In the lymphoma model, the survival of the SUDHL-1-bearing mice was significantly prolonged by the treatment with 90Y-HeFi-1 compared with the controls (P < 0.001). In summary, radiolabeled HeFi-1 is very promising for the treatment of CD30-expressing leukemias and lymphomas, and the combination regimen of 211At-HeFi-1 with unmodified HeFi-1 enhanced the therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)8444-8448
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number20
DOIs
StatePublished - May 15 2007

Keywords

  • Monoclonal antibody
  • Radioimmunotherapy
  • α-emitter
  • β-emitter

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1'. Together they form a unique fingerprint.

  • Cite this

    Zhang, M., Yao, Z., Patel, H., Garmestani, K., Zhang, Z., Talanov, V. S., Plascjak, P. S., Goldman, C. K., Janik, J. E., Brechbiel, M. W., & Waldmann, T. A. (2007). Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proceedings of the National Academy of Sciences of the United States of America, 104(20), 8444-8448. https://doi.org/10.1073/pnas.0702496104